# Naloxone Economic View
## SUMMARY REPORT
### Table of Contents

**ONE | INTRODUCTION**
- Background ................................................................. 4
- Opioid Overdose ............................................................ 4
- Preventing Overdose Fatalities: Naloxone ..................... 6
- Naloxone Access ........................................................... 7
- OTC Naloxone ............................................................... 8

**TWO | NALOXONE DISTRIBUTION** ........................................... 9
- Distribution Data ........................................................... 9
- Opioid Settlement Agreements – Provisions for Naloxone ..... 11

**THREE | PAYING FOR NALOXONE DISPENSED IN PHARMACIES** ........... 13
- Payor Roundtable: Considerations for Coverage of Over-the-Counter Medications ................................................... 14
- Meeting Findings ........................................................... 14

**FOUR | RX TO OTC SWITCH CONSIDERATIONS** .......................... 16
- Insurance Coverage ......................................................... 16
- Access and Cost-Shifting to Consumers ....................... 17
- Supply Chain ............................................................... 17
- Drug Shortages ............................................................ 18

**FIVE | CONCLUSION** .......................................................... 18
- Appendix: Payor Roundtable Agenda ......................... 19
- References ................................................................. 21
INTRODUCTION

The Reagan-Udall Foundation for the FDA (FDA Foundation), in collaboration with the U.S. Food and Drug Administration (FDA), conducted a research project to explore the current distribution of naloxone in the U.S. and the potential economic impacts of a change in the prescription-only status of naloxone.

Drug overdose deaths in the U.S. top 100,000 annually. The U.S. Centers for Disease Control and Prevention (CDC) recommend additional policy measures to address this issue, including expanding distribution and use of naloxone, and overdose prevention education. The White House recently proposed a state model law facilitating expanded naloxone access, which includes required health insurance coverage. Given the public health importance of naloxone, many jurisdictions have implemented policies to increase its availability.

In 2018, FDA hosted a meeting to solicit input and advice on strategies to increase naloxone availability. Some experts have suggested transitioning naloxone from a prescription to an over-the-counter (OTC) medical product as one option to decrease disparities in access. Also, former FDA Commissioners have spoken about the importance of increasing the availability of naloxone and efforts to encourage the development of an OTC product.

The transition of prescription products to nonprescription (OTC) is assumed to yield an economic benefit to both the consumer and the health care system, as well as increase overall sales of a product. One concern, however, is that a typical health insurance plan prescription drug benefit, whether public or private, may not include coverage of OTC products, thus increasing out-of-pocket (OOP) cost to the consumer if the OTC price is greater than a drug benefit copay.

2 An opioid antagonist that can reverse opioid overdose.
The distribution and payor mix for naloxone differs from the traditional prescription-only product. As a result of a mix of standing orders and provision through community-based organizations, the economic implications of a switch to OTC status are less obvious from a consumer perspective. While the OOP cost for consumers is often zero for naloxone – either due to a zero-copay structure from their insurance or because the product is provided free of charge by community-based organizations – the posture of these same providers may change with a switch to OTC status.

To explore potential impacts of an OTC formulation of naloxone becoming available, particularly on payor decision-making and consumer access and OOP costs, the FDA Foundation performed the following analyses:

1. Describe the current distribution and funding mix for naloxone access, yielding the proportion of naloxone costs supported by commercial insurance, by Medicaid programs, by Medicare/Medicare Advantage, by state and federal funding, and directly by patients.

2. Describe the policy of those payors related to general coverage of nonprescription products, including description of payors that cover OTC products. For the patient/consumer payment, describe the availability/applicability of flexible spending accounts and health spending accounts.

3. Explore potential impacts of policy changes to expand coverage for nonprescription products, such as naloxone, in a closed-door payor roundtable.

Background

Opioid Overdose

Opioid overdose persists as a major public health issue in the United States, with rates increasing substantially since 2013 (Figure 1: Three Waves of Opioid Overdose Deaths). Fatal opioid overdoses increased by 13% from 2020 to 2021, largely driven by increases in deaths due to fentanyl and its analogs (Table 1). Every day, 187 people die from an opioid overdose, 24% of which involve a prescription medication.

---


Opioid overdoses increased during the COVID-19 pandemic, and disproportionately so for Black Americans and residents of poor, urban areas.\textsuperscript{13,14} Despite the increase in opioid overdoses during this time, the number of naloxone prescriptions dispensed per week declined and remained low.\textsuperscript{15}

Risk factors for overdose include: changes in tolerance after a period of low- or non-use, changes in drug supply, mixing opioids with respiratory depressants (benzodiazepines, alcohol, sedatives) or stimulants (cocaine, methamphetamine), chronic health conditions (asthma, chronic obstructive pulmonary disease, mental health conditions, substance use disorders), higher doses of prescribed opioids ($\geq$ 100 morphine milligram equivalents), and a history of past overdose(s).\textsuperscript{16}

\textbf{Figure 1: Three Waves of Opioid Overdose Deaths}

Three Waves of Opioid Overdose Deaths

\begin{table}
\centering
\begin{tabular}{|c|c|c|c|c|c|c|c|c|c|c|c|c|c|c|c|}
\hline
\hline
Deaths per 100,000 & 4 & 6 & 8 & 10 & 12 & 14 & 16 & 18 & 20 & 22 & 24 & 26 & 28 & 30 & 32 & 34 & 36 & 38 & 40 & 42 & 44 \\
\hline
\end{tabular}
\caption{Three Waves of Opioid Overdose Deaths}
\end{table}

### Table 1: U.S. Overdose Deaths by Drug Type

<table>
<thead>
<tr>
<th>Drug Type</th>
<th>Deaths (2020)</th>
<th>Deaths (2021)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synthetic opioids (e.g., fentanyl)</td>
<td>57,834</td>
<td>71,238</td>
</tr>
<tr>
<td>Psychostimulants (e.g., methamphetamine)</td>
<td>24,576</td>
<td>32,856</td>
</tr>
<tr>
<td>Cocaine</td>
<td>19,927</td>
<td>24,538</td>
</tr>
<tr>
<td>Natural/semi-synthetic opioids (prescription)</td>
<td>13,722</td>
<td>13,503</td>
</tr>
</tbody>
</table>

### Preventing Overdose Fatalities: Naloxone

Naloxone saves lives. The National Institute on Drug Abuse (NIDA) Director Dr. Nora Volkow has stated, “We don’t need to keep asking if these things work. Instead, we must find ways to help providers, people, and communities overcome the barriers to implementing these valuable interventions.”

Naloxone prevents death from overdose by blocking the effect of opioids in the body. Naloxone only works to counteract the effects of opioid drugs, but has no effect in reversing the effects of other substances such as alcohol, benzodiazepines, or stimulants. The reversal effects of naloxone are temporary – restoring breathing within 2-3 minutes with effects lasting 30-90 minutes. More than one dose of naloxone may be necessary to prevent death from an overdose depending on the amount of opioid ingested. In addition, naloxone is not harmful if administered in the setting of a non-opioid drug overdose. Naloxone is administered as a nasal spray or as an intramuscular, subcutaneous, or intravenous injection. Naloxone products and properties are listed in Table 2.

### Table 2: Naloxone Products

<table>
<thead>
<tr>
<th>Brand Availability</th>
<th>Injectable</th>
<th>Intranasal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes (Zimhi™)</td>
<td>Yes (Narcan®, Kloxxado®)</td>
</tr>
<tr>
<td>Generic Availability</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Administration</td>
<td>The proper dose must be drawn up from a vial, or it is provided in prefilled syringes. Usually, it is injected with a needle into muscle, although it also may be administered into a vein or under the skin. Zimhi™ is a prefilled syringe that can be injected into the muscle or under the skin.</td>
<td>These devices contain a prefilled dose that is sprayed into one nostril while the person experiencing an overdose lays on their back.</td>
</tr>
</tbody>
</table>

\[18\] Opioid drugs include: codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, methadone, tramadol, fentanyl, buprenorphine, heroin.
**Naloxone Access**

Barriers and facilitators to naloxone access are listed in Table 3. Opioid reversal agents are only useful if present and administered at the scene of an overdose. Bystanders were present for approximately 46% of fatal overdoses in 2021, and the CDC estimates that only one naloxone prescription was provided per 69 high-dose opioid prescriptions both examples of missed opportunities for intervention.

All over the country, putting naloxone in the hands of first responders has saved countless lives. And because it is such a safe drug, it can be put directly in the hands of people who use opioids, their loved ones and friends, and anybody else who may find themselves in a position to save the life of someone overdosing on an opioid. Yet despite the safety and lifesaving value of this drug, there are impediments to widespread use. Naloxone is not available over the counter, which could ease access. Doctors don’t always prescribe it to patients who need it, pharmacies don’t always stock it, the price may be prohibitive when they do stock it. While many states now have standing orders allowing anyone to get it from the pharmacist without a prescription, people often do not know that. People who offer harm reduction in communities are also affected by costs and product shortages.

- **NIDA Director Dr. Nora Volkow**

---


Table 3: Naloxone Access Barriers and Facilitators

<table>
<thead>
<tr>
<th>Barriers</th>
<th>Facilitators</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescription-only status</td>
<td>Nonprescription status</td>
</tr>
<tr>
<td>Insurance coverage – copay or coinsurance, prior authorization (PA)</td>
<td>Statewide standing orders or pharmacist prescriptive authority for providing</td>
</tr>
<tr>
<td>requirement</td>
<td>naloxone (no patient-specific prescription)</td>
</tr>
<tr>
<td>Insurance prescription fill limits (e.g., may only fill the prescription</td>
<td>Co-prescribing of naloxone with an opioid</td>
</tr>
<tr>
<td>twice in 30 days)</td>
<td>Affordable or free naloxone</td>
</tr>
<tr>
<td>Physical locations of the product – limited to pharmacies (medication/</td>
<td>Legislation requiring coverage by insurance without fill limits or PA</td>
</tr>
<tr>
<td>pharmacy deserts), more limited access in nonurban or rural vs. urban</td>
<td>requirements</td>
</tr>
<tr>
<td>areas</td>
<td>Community distribution – harm reduction, schools, libraries, prisons,</td>
</tr>
<tr>
<td></td>
<td>vending machines</td>
</tr>
<tr>
<td>Cost – 20% of adults with opioid use disorder (OUD) are uninsured</td>
<td>Prescriber, dispenser, and layperson liability immunity</td>
</tr>
<tr>
<td>Drug shortages</td>
<td>FDA supply chain regulations for harm reduction organizations (see guidance)</td>
</tr>
<tr>
<td></td>
<td>– can also be barrier</td>
</tr>
<tr>
<td>Bias and stigma (requesting the drug from a health care professional or</td>
<td>Prohibition on life insurance companies taking adverse actions against people</td>
</tr>
<tr>
<td>carrying the drug implies illicit drug use)</td>
<td>who have obtained naloxone</td>
</tr>
<tr>
<td>Structural racism</td>
<td></td>
</tr>
</tbody>
</table>

Nonprescription Naloxone

A potential shift in prescription-only to nonprescription status for medications requires consideration on the part of sponsors/manufacturers, regulators, payors, health professionals, and consumers. Naloxone is not currently available as an over-the-counter (OTC, nonprescription) medication. Nonprescription drugs meet the following criteria:25

- The drug has a high safety margin.
- The drug can be used appropriately by consumers for self-diagnosed conditions.
- The health practitioner is not required for safe and effective use.
- The drug has a low potential for misuse and abuse.
- The product can be adequately labeled to allow safe and effective use without additional instruction.

Numerous professional organizations have called for OTC naloxone as a step to improve accessibility. They recommend removal of prescription status for all formulations or nonprescription status of at least one formulation, regardless of manufacturer requests.

The FDA has taken steps to support availability of nonprescription naloxone on the market, and at the time of this report two manufacturers have submitted applications to the FDA for a nonprescription naloxone nasal spray. In addition, the FDA conducted a naloxone OTC label comprehension study to determine whether consumers understood key statements on the label, which was a major step toward safe and effective use of naloxone in the OTC setting.

TWO | NALOXONE DISTRIBUTION

Distribution Data

In 2022, we sought to estimate how many doses of naloxone are distributed in the United States annually and what proportion of doses are distributed through pharmacies versus other avenues. We engaged with experts in the field to understand unique distribution considerations for naloxone, including representatives from manufacturing, trade organizations, and academia. A convenience sample of three major manufacturers provided the number of naloxone units distributed in calendar year 2021. These data were cross-referenced with IQVIA National Sales Perspectives (NSP) data queried for January 2021-December 2021 (extracted July 2022 and verified December 2022). To prevent double counting, we did not include doses reported by manufacturers or trade organizations.

---

36 For the purposes of this analysis, we counted one nasal spray, one prefilled auto-injector, and one vial as a “dose” of naloxone.
manufacturers if there was a possibility these doses were counted in IQVIA data. Our analysis is likely an underestimate of the number of doses distributed in 2021. Naloxone is currently distributed by pharmacies, health care facilities, and organizations outside the traditional health care system, including harm reduction organizations, first responders, prisons, and schools and universities.

In combining typical prescription drug distribution data with data regarding naloxone distribution outside of the traditional health care system, we estimate that approximately 16.95 million doses of naloxone were distributed in the U.S. in 2021. According to typical prescription drug distribution data, 2.64 million and 6.61 million doses were distributed to retail pharmacies and other health care facilities, respectively (Figure 2). An estimated 7.7 million additional doses were distributed outside retail pharmacies and traditional health care facilities; these doses have largely not been captured in typical drug distribution data. Unlike most prescription medical products, a significant proportion of naloxone is not distributed through a pharmacy or other health care facilities. Millions of naloxone doses are distributed to local health departments, harm reduction organizations, first responders, schools, and other community organizations annually. Naloxone that is distributed outside the traditional health care system may not be captured in typical sources of data about medical product distribution.

Figure 2: Naloxone Doses Distributed in 2021 (in millions)
Opioid Settlement Agreements – Provisions for Naloxone

Future naloxone distribution will be affected by opioid settlement agreements (Table 4). As of November 30, 2022, the opioid manufacturers, distributors, and retailers named in lawsuits related to opioid misuse have agreed to settlements with state, local, and tribal governments. Many of these settlements include funding for naloxone access, and some settlements include details regarding naloxone purchase or donation. Other settlements will be distributed according to state-drafted Memoranda of Understanding (MOU) outlining how the settlement money is intended to be allocated to state funds, cities, counties, and defined localities. Within these MOUs, provisions for expanding naloxone access are addressed in the following ways:

1. Support “Naloxone Plus” strategies, which work to ensure that individuals who have received naloxone to reverse the effects of an overdose are then linked to treatment programs or other appropriate services.

2. Increase availability and distribution of naloxone and other drugs that treat overdoses for first responders, overdose patients, individuals with OUD and their friends and family members, schools, community navigators and outreach workers, persons being released from jail or prison, or other members of the general public.

3. Provide free naloxone to anyone in the community via public health entities.

4. Provide training and education regarding naloxone and other drugs that treat overdoses for first responders, overdose patients, patients taking opioids, families, schools, community support groups, and other members of the general public.

5. Enable school nurses and other school staff to respond to opioid overdoses, and provide them with naloxone, training, and support.

6. Expand, improve, or develop data tracking software and applications for overdoses/naloxone revivals.

---

### Table 4: Summary of Opioid Settlement Agreement Funding for Naloxone

<table>
<thead>
<tr>
<th>Settlement</th>
<th>Naloxone Provisions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MANUFACTURERS</strong></td>
<td></td>
</tr>
<tr>
<td>Purdue</td>
<td>Up to $6 billion</td>
</tr>
<tr>
<td>Teva</td>
<td>$3 million in cash over 13 years</td>
</tr>
<tr>
<td></td>
<td>$240 million in lieu of naloxone product (determined by state)</td>
</tr>
<tr>
<td>Allergan/AbbVie</td>
<td>$2.37 billion</td>
</tr>
<tr>
<td>Endo</td>
<td>$450 million over 10 years; state-specific settlements</td>
</tr>
<tr>
<td><strong>DISTRIBUTORS</strong></td>
<td></td>
</tr>
<tr>
<td>J&amp;J, McKesson, Amerisource-Bergen, Cardinal Health combined settlement</td>
<td>$26 billion distributed over 18 years; state-specific allocations</td>
</tr>
<tr>
<td><strong>RETAILERS</strong></td>
<td></td>
</tr>
<tr>
<td>CVS</td>
<td>$5 billion over 10 years</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Walgreens</td>
<td>$5.7 billion over 15 years</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>WalMart</td>
<td>$3.1 billion</td>
</tr>
<tr>
<td>Rite Aid of MA</td>
<td>$177,000</td>
</tr>
<tr>
<td>Ride Aid &amp; Giant Eagle</td>
<td>$2.2 million allocated to Ohio Lake and Trumbull counties</td>
</tr>
</tbody>
</table>
THREE | PAYING FOR NALOXONE DISPENSED IN PHARMACIES

Naloxone costs at retail pharmacies are covered by various payors including, but not limited to: commercial insurance, Medicaid programs, Medicare and Medicare Advantage programs, Veterans Affairs, State and Federal Funding (e.g. SAMHSA grants), or out-of-pocket (OOP). Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) may ameliorate naloxone OOP costs for people enrolled in these programs.

Payor coverage and OOP costs for naloxone from 2014-2018 were assessed using pharmacy claims data in an article by Peet, et al. OOP costs increased sharply for the uninsured from 2015 to 2016: “For uninsured patients, the mean OOP cost of Evzio® was 14.9 times the mean OOP cost of Narcan® and 16.02 times the mean OOP cost for generic naloxone.” Since then, commercial insurance providers (e.g., Optum) have instituted low- or no-copay programs for naloxone, ensuring that at least one formulation is available at no cost or a discounted price.

Most private insurance plans are required to cover preventive services assigned a United States Preventive Services Task Force (USPSTF) grade A or B without a copay. However, no recommendation for “preemptive prescribing of naloxone for mitigating overdose risk” currently exists. Despite this, the cost of naloxone is generally covered by most insurance policies. All state Medicaid Plans reimburse for at least one naloxone formulation, though constraints to obtaining the medication, such as PA requirements, may exist. The Department of Veterans Affairs has eliminated copayment for all opioid antagonists.

Insurance coverage of OTC medications varies from plan to plan. Currently, 49 state Medicaid plans cover OTC medications. Stipulations for coverage may include requiring a prescription written by a licensed provider for the OTC product, PA, or quantity or fill limit policies. OTC medications may be covered by a supplemental benefit of a Medicare Advantage Plan.

---

How naloxone coverage may be affected by a prescription to nonprescription switch was explored during a payor roundtable convened in October 2022 (meeting agenda can be found in the Appendix).

Payor Roundtable: Considerations for Coverage of Over-the-Counter Medications

The FDA Foundation convened a virtual roundtable meeting to identify factors considered in decision-making processes for whether to include OTC medications as part of health/pharmacy insurance benefits and coverage. This section summarizes the discussion from the meeting of public and private payor representatives and experts (n=11), knowledgeable about the economic implications of medical products transitioning from prescription to nonprescription status. The focus of the meeting was to understand 1) the factors considered when covering nonprescription medications and 2) how these factors may affect consumer access to medication.

The FDA Foundation hosted this conversation with the intention of providing insight to FDA and other federal agencies regarding the payor decision-making process for covering nonprescription medications.

Meeting Findings

Participants shared that payors make nonprescription drug coverage decisions by considering a number of elements, including:

- Legal mandates (e.g., Affordable Care Act requirements),
- Medications recommended as part of USPSTF Grade A and B recommendations,
- Clinical merit,
- Fiscal considerations,
- Relative cost of product (portion of pharmacy benefit budget, rebates, manufacturer incentives),
- Policy implications (particularly program integrity),
- Political climate, and
- Insurance industry standards.

The posture of payors towards OTC coverage has changed over the past decade with the increase in market share of high-cost specialty medications. Today, payors pay particular attention to specialty drug spending, with less of an emphasis on products that may move nonprescription status. Further, payors are more willing to consider including OTCs in the pharmacy benefit, particularly life-saving drugs or medications that have off-setting cost benefits. In addition, payors stated that they would likely cover a prescription naloxone formulation if it was a different delivery system from the nonprescription status version, but insurance coverage of nonprescription medications is more complex than direct consumer payment. Technical and logistical issues at the pharmacy, including documentation of the claim, often in the form of a prescription, is often required for program integrity and fraud protection.
Additional considerations of payors include:

1. **State Medicaid Programs:** Although Medicaid coverage of nonprescription medications is optional, 49 state Medicaid programs cover OTCs (Figure 3: Drug Overdose Mortality by State and OTC Medication Coverage by State Medicaid Plans). Providing this coverage requires time (~3-6 months) to add an OTC. If Federal funds are being used to cover an OTC product, a prescription from a provider is required for the OTC drug. Coverage is specific to the state and state plans administering Medicaid benefits.

2. **Medicare Programs:** Under current law, Medicare may not pay for OTCs. No precedent exists for the coverage of a life-saving OTC medication. Medicare Advantage Part D programs (prescription drug benefits offered under Medicare Advantage), may, and often do, cover OTCs. Supplemental benefits may also cover OTCs; coverage is plan-specific.

*Figure 3: Drug Overdose Mortality by State and OTC Medication Coverage by State Medicaid Plans*  

---

**Drug Overdose Mortality**

*By State*

**Deaths per 100,000**

- ➥ >50
- ➤ 39 — 49.2
- ➤ 24.9 — 38.2
- ➤ <23

Solid = OTC coverage by state

Diagonal stripes = No OTC coverage by state Medicaid plan(s)

---

FOUR | RX-TO-OTC SWITCH CONSIDERATIONS

Moving medications to OTC status provides consumers access to medication without the time and expense of a health care provider interaction required to obtain a prescription. All stakeholders, including payors, may benefit when consumers can directly access effective treatments. Payors may benefit from eliminating costs for unnecessary clinic visits or testing. In addition, having OTC medication readily available in convenient retail locations and online, may help address disparities in access to health care. Conversely, a shift from prescription-only to nonprescription status may create negative consequences when it comes to paying for such products, as the medication cost may switch from a covered insurance benefit to a fully OOP consumer-borne cost.

Insurance Coverage
As discussed by roundtable participants, many private insurance plans, Medicaid, and Medicare Advantage plans include OTC medications in plan benefits. Depending on payor type and payor policies, OTC medications may be partially or wholly covered by the payor. Impact of a naloxone prescription to nonprescription status switch may be minimal if insurance plans deem coverage to be essential and cost-effective. With any potential OTC switch, payors need sufficient time to prepare to ensure access for their beneficiaries/covered lives.

The 2020 CARES Act allows for coverage of OTC medications by HSAs and FSAs. Consumers with these benefits would be able to offset nonprescription naloxone OOP costs.

Full coverage of nonprescription naloxone without a copay or coinsurance facilitates access. Simplifying the purchase process (e.g., not requiring extra steps such a prescription for the nonprescription formulation or prior authorization) may also reduce anxiety and stigma associated with buying naloxone. Insured persons may worry about other plan members (e.g., parents, if the covered person is a young adult), employers, or their insurance company becoming aware of the naloxone claim and potential repercussions. Assurance by the health plan that obtaining naloxone is confidential and will not affect overall health care coverage is an important step in breaking down barriers to access.
State mandates for coverage of opioid reversal agents and USPSTF assignment of a Grade A or B recommendation for using naloxone to manage opioid overdose would help ensure national naloxone coverage without cost-shifting to consumers. Such actions also create a basis for combatting stigma – setting standards supporting conversations about overdose and policies to ensure naloxone is immediately available for use by bystanders outside of healthcare settings.

**Access and Cost-Shifting to Consumers**

Nonprescription naloxone could be sold outside of pharmacies, therefore increasing access, and reducing pharmacy deserts. Eliminating these access deficits also helps to reduce the stigma associated with prescribing, dispensing, and carrying naloxone.47

Depending on drug price, broader access may be countered by a high OOP cost, becoming cost-prohibitive in areas with the highest need. Part of the difficulty in achieving universal, low-barrier, nonprescription access to naloxone lies in the price to consumers. Nonprescription naloxone nasal spray will likely be costly, even if multiple generics become available to create market competition. Further, approval of nonprescription naloxone via the New Drug Application pathway may provide manufacturers with patent exclusivity, which would limit the potential price competition of generic alternatives.

Beyond pricing and coverage questions, supply chain dynamics will also be affected in a prescription to nonprescription switch.

**Supply Chain**

The FDA issued guidance regarding the Public Health Emergency exclusion as it applies to the Drug Supply Chain Security Act (DSCSA). This guidance clarifies exemptions from the DSCSA for harm reduction organizations reporting difficulties acquiring naloxone.48 Approval of nonprescription naloxone product would allow organizations to purchase the medication directly, eliminating barriers which make purchasing naloxone more difficult. It is likely that nonprescription status would more efficiently put naloxone in the hands of people on the front lines of the overdose crisis.

---


Drug Shortages
As access increases with the availability of nonprescription naloxone, the potential for drug shortages should also be considered. More product will be needed to stock shelves in pharmacy and non-pharmacy retailers. State and local programs currently providing naloxone are not able to keep up with demand and it is imperative that product shortages do not compound this problem. How the opioid settlements will affect naloxone supply remains to be seen. Teva, CVS, Walgreens and Rite Aid of MA settlements contain provisions for naloxone distribution, and states’ funding for naloxone purchase will also increase. Higher demand must be met with the adequate supply for nonprescription naloxone to truly improve

FIVE CONCLUSION

Naloxone is an important public health tool which should be available to anyone in the position to assist someone experiencing opioid overdose. A prescription to nonprescription switch is a potential mechanism to expand naloxone availability, although nonprescription naloxone alone is not the sole solution to expanding access. Such a switch should be a component within the context of a larger strategy addressing expanded distribution, insurance coverage, cost to the consumer, and production keeping pace with high demand.


AGENDA
Meeting Purpose: Explore factors considered in decision-making processes for whether to include over-the-counter (OTC) medications as part of health/pharmacy insurance benefits and coverage. This virtual, invitation-only roundtable will include a variety of public and private payor representatives and experts to discuss the economic implications of medical products transitioning from prescription to OTC status.

Background:
A potential shift in prescription-only to OTC status for medications requires consideration on the part of sponsors/manufacturers, regulators, payors, health professionals, and consumers. In recent years, there have been efforts to increase access to certain drugs at both the state and federal level. Examples include shifting products from prescription to nonprescription (or OTC) status or expanding eligible individuals and circumstances for prescribing medications (e.g., oral contraceptives, naloxone, and insulin) and devices (e.g., COVID-19 test kits and hearing aids). Moving medications to OTC status provides consumers access to medication without the time and expense of a health care interaction required to obtain a prescription. All stakeholders, including payors, may benefit when consumers can directly access effective treatments. Payors may benefit from not having to pay for unnecessary clinic visits or testing. In addition, having OTC medication readily available in convenient retail locations, and online, may help address disparities in access to health care. However, a shift from prescription-only to OTC status may create negative consequences when it comes to paying for such products, as the medication cost may switch from a covered insurance benefit to a fully out-of-pocket cost. (Although conversion to nonprescription status does not always equate with a shift to uncovered status: some state Medicaid plans as well as Medicare Advantage plans, cover some OTC medications.)

This conversation is intended to provide insight to FDA and other federal agencies regarding the payor decision-making process for covering nonprescription medications.
12:30 p.m.  Welcome and ‘Ground Rules’
Speaker: Susan C. Winckler, RPh, Esq, Chief Executive Officer, Reagan-Udall Foundation for the FDA

12:35 p.m.  Opening Remarks from U.S. Food and Drug Administration
Speaker: Marta Sokolowska, Deputy Center Director for Substance Use and Behavioral Health, Center for Drug Evaluation and Research

12:40 p.m.  The Changing Consumer Landscape
Speaker: Winckler

12:50 p.m.  Participant Introductions
Moderator: Winckler
When called on, please share your name, affiliation, and role within your organization. (Please keep your introductions to ~30 seconds each.)

1 p.m.  Group Discussion
Moderator: Winckler
Key Question:
- What factors do payors consider when deciding when and at what level to include OTC medications as part of a pharmacy benefit?

Scenarios to Explore:
- Under what circumstances are payors required to cover OTCs? If not required, when would payors typically cover OTCs voluntarily?
- When a product has both prescription and OTC options, how does that factor into coverage decisions?
- If one dosage form is OTC but another dosage form is prescription, how might that impact coverage decisions?
- If the insured individual is given an OTC medication during inpatient care, and that OTC medication needs to be continued in the outpatient setting, how does that impact the outpatient OTC medication coverage decisions?
- What are the considerations for medical products that payors cover with no copay that transition from prescription-only to OTC?

2:50 p.m.  Next Steps
Speaker: Winckler

3 p.m.  Adjournment
References

Funding Disclosure: This activity is one part of a multi-part Foundation project related to substance use disorder. This project is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of an award of $80,000 of federal funds (100% of the project). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA, HHS, or the U.S. Government. For more information, please visit [FDA.gov](http://FDA.gov).